HIGHLIGHTS
- who: Maria A. Pantaleo from the Division in Medical Oncology, IRCSS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy have published the research: A multicenter, dose-finding, phase 1b study of imatinib in combination with alpelisib as third-line treatment in patients with advanced gastrointestinal stromal tumor, in the Journal: (JOURNAL)
- what: This study investigated the safety tolerability and efficacy of alpelisib a phosphatidylinositol 3-kinase inhibitor used in combination with imatinib in patients with advanced GIST who had failed prior therapy with both imatinib and sunitinib. The aim of the study was to determine the . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.